S-adenosyl methionine (SAM-e) for depression in adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Galizia, Ilaria ^a   Oldani, Lucio ^b   Macritchie, Karine ^c   Amari, Erica ^d   Dougall, Dominic ^e   Jones, Tessa N ^f   Lam, Raymond W ^d   Massei, Guido Jacopo ^g   Yatham, Lakshmi ^d   Young, Allan H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^f CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; SYSTEMATIC REVIEW;

EID: 84990912694     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011286     Document Type: Article

References (58)

1. Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of s-adenosyl-l-methionine (SAMe) upon depressive symptoms. Journal of Psychiatric Research 1976;13(1):43-54.
2. Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2 [Cochrane Reviewers' Handbook 4.2.2 updated December 2003]. 4.2.2. Chichester, UK: Wiley & Sons, Ltd, 2004.
3. Algeri S, Catto E, Curcio M, Ponzi F, Stamentinoli G. Changes in rat brain noradrenaline and serotonin after administration of S-adenosylmethionine. Biochemical and pharmacological roles of adenosylmethionine and the central nervous system. New York: Permagon Press, 1979:81-7.
4. Altman DG, Bland JM. Statistics notes: Presentation of numerical data. BMJ 1996;312:572.
5. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III). Washington DC: American Psychiatric Association, 1980.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington DC: American Psychiatric Association, 1994.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000.
9. American Psychiatric Association. Practice guideline for the Treatment of Patients with Major Depressive Disorder, Third edition. 2010.
10. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al . Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007954]
11. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Canadian Journal of Psychiatry 2007;52:46-54.
12. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
13. Bottiglieri T. S-adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotrophic molecule. American Journal of Clinical Nutrition 2002;78:1151S-7S.
14. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurologica Scandinavica. Supplementum 1994;154:7-14.
15. Royal Pharmaceutical Society of Great Britain, British Medical Association. British National Formulary. British Medical Association, September 2013.
16. Byford S, Barrett B, Despiégel N, Wade A. Impact of treatment success on health service use and cost in depression: longitudinal database analysis. Pharmacoeconomics 2011 Feb;29(2):157-70. [DOI: 10.2165/11537360-000000000-00000]
17. Cantoni GL. The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate. Journal of the American Chemical Society 1952;74(11):2942-3.
18. Carney MW, Chary TK, Bottiglieri T, Reynolds EH. The switch mechanism and the bipolar/unipolar dichotomy. British Journal of Psychiatry 1989;154:48-51.
19. Chavez M. SAMe: S-Adenosylmethionine. American Journal of Health-System Pharmacy 2000;57(2):119-23.
20. Craig D, Rice S, University of York, NHS Centre for Review and Dissemination. NHS Economic Evaluation Database Handbook. York, UK: Centre for Reviews and Dissemination, University of York, 2007, 2007.
21. Curcio M, Catto E, Stramentinoli G, Algeri S. Effect of S-adenosyl-L-methionine on serotonin metabolism in rat brain. Progress in Neuro-Psychopharmacology 1978;2(1):65-71.
22. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. Journal of Clinical Psychiatry 2010;71 Suppl E1. [DOI: 10.4088/JCP.9058se1c.04gry]
23. Delle Chiaie R, Pancheri P, Scapicchio P . Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1, 4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. The American Journal of Clinical Nutrition 2002;76(5) :1172S-6S.
24. DerSimonian R, Laird N. Meta-analysis in Clinical Trials. Controlled Clinical Trials 1986;7:177-88.
25. Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-Adenosyl methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Movement Disorders 2000;15 (6):1225-9.
26. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
27. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
28. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. Journal of Clinical Psychiatry 1983;44(8, Pt2):8-11.
29. Furukawa TA, Barbui C, Cipriani A, Brambillac P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
30. Goldberg D, Fawcett J. The importance of anxiety in both major depression and bipolar disorder. Depression and Anxiety 2012:1-8.
31. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al.The economic burden of depression in the United States: how did it change between 1990 and 2000?. Journal of Clinical Psychiatry 2003;64(12):1465-75.
32. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
33. Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharamacotherapy 2004;24(11):1501-7.
34. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960;23:56-62.
35. Henkel V, Mergi R, Allgaier AK, Kohnen R, Möller HJ, Hegeri U. Treatment of depression with atypical features: A meta-analytic approach. Psychiatry Research 2006;141:89-101.
36. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343. [DOI: http://dx.doi.org/10.1136/bmj.d5928]
37. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008.
38. Craig Nelson J. S-Adenosyl Methionine (SAMe) augmentation in major depressive disorder. American Journal of Psychiatry 2010;167:889-91. [: 10.1176/appi.ajp.2010.10040627]
39. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry 1990;147:591-5.
40. Kessler RC. The costs of depression. Psychiatric Clinics of North America 2012 March;35(1):1-14. [DOI: 10.1016/j.psc.2011.11.005]
41. McCrone P, Dhanasiri S, Pate A, Knapp M, Lawton-Smith S. Paying the Price.The cost of mental health care in England to 2026. King's Fund, 2008.
42. Kresge N, Tabor H, Simoni RD, Hill RL. An escape from Italy, the discovery of S-adenosylmethionine, and the biosynthesis of creatine by Giulio L. Cantoni. Journal of Biological Chemistry 2005;280:e35.
43. Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux C, Altesman R, Jones B. Open trial of S-adenosylmethionine for treatment of depression. American Journal of Psychiatry 1984;141:448-50.
44. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
45. Morelli V, Zoorob RJ. Alternative therapies: Part I. Depression, diabetes, obesity. American Family Physician 2000;62(5):1051-60.
46. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349(9063):1436-42.
47. Nemeroff CB. Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry 2007;68 Suppl 8:17-25.
48. National Institute for Health and Care Excellence. Depression in adults, The treatment and management of depression in adults. NICE clinical guideline 90 October 2009.
49. Otero-Losado ME, Rubio MC. Acute effects of S-adenosylmethionine on catecholaminergic central function. European Journal of Pharmacology 1989a;163:353-6.
50. Otero-Losado ME, Rubio MC. Acute changes in 5HT metabolism after S-adenosylmethionine administration. General Pharmacology 1989b;20:403-6.
51. Papakostas GI, Alpert JE, Fava XX. SAMe in the treatment of depression: a comprehensive review of the literature. Current Psychiatry Reports 2003;5:460-6.
52. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database of Systematic Reviews 200, Issue 4. [DOI: 10.1002/14651858.CD002235.pub2]
53. Shippy RA, Mendez D, Jones K, Cergnul I, Karpiak SE. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry 2004;4:38.
54. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. The Journal of Mental Health Policy and Economics 2006 Jun;9(2):87-98.
55. Sugden C. One-carbon metabolism in psychiatric illness. Nutrition Research Reviews 2006;19:117-36.
56. World Health Organization. Mental disorders: glossary and guide to their classification in accordance with the ninth revision of the international classification of diseases. Geneva: WHO, 1978.
57. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Geneva: World Health Organisation, 1992.
58. Williams AL, Girard C, Jui D, Sabina A, Katz Dl. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clinical and Investigative Medicine 2005;28:132-9.